Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 24
Submit an article Journal homepage
110
Views
0
CrossRef citations to date
0
Altmetric
Editorial

KRASG12C mutation in metastatic colorectal cancer: a new target

Rebecca Ibrahim1 International Department,Gustave Roussy Cancer Campus, Villejuif, 94800, France
,
Khalil Saleh1 International Department,Gustave Roussy Cancer Campus, Villejuif, 94800, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2985-2202
ORCID Icon,
Claude Chahine1 International Department,Gustave Roussy Cancer Campus, Villejuif, 94800, France
,
Rita Khoury1 International Department,Gustave Roussy Cancer Campus, Villejuif, 94800, France
,
Nadine Khalife2 Department of Head & Neck Oncology,Gustave Roussy Cancer Campus, Villejuif, 94800, France
&
Axel Lecesne1 International Department,Gustave Roussy Cancer Campus, Villejuif, 94800, France
Pages 1641-1643 | Received 19 Mar 2023, Accepted 18 Jul 2023, Published online: 21 Aug 2023

References

  • Rawla P , SunkaraT, BarsoukA. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol.14(2), 89–103 (2019).
  • Tariq K , GhiasK. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol. Med.13(1), 120–135 (2016).
  • Won DD , LeeJI, LeeIK, OhS-T, JungES, LeeSH. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer17(1), 403 (2017).
  • Jancík S , DrábekJ, RadziochD, HajdúchM. Clinical relevance of KRAS in human cancers. J. Biomed. Biotechnol.2010, 150960 (2010).
  • Neumann J , Zeindl-EberhartE, KirchnerT, JungA. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract.205(12), 858–862 (2009).
  • Ostrem JM , PetersU, SosML, WellsJA, ShokatKM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature503(7477), 548–551 (2013).
  • Jones RP , SuttonPA, EvansJPet al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br. J. Cancer116(7), 923–929 (2017).
  • Reck M , CarboneDP, GarassinoM, BarlesiF. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann. Oncol.32(9), 1101–1110 (2021).
  • Skoulidis F , LiBT, DyGKet al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med.384(25), 2371–2381 (2021).
  • Fakih MG , KopetzS, KubokiYet al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol.23(1), 115–124 (2022).
  • Weiss J , YaegerRD, JohnsonMLet al. LBA6 KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann. Oncol.32(Suppl. 5), S1294 (2021).
  • Goebel L , MüllerMP, GoodyRS, RauhD. KRasG12C inhibitors in clinical trials: a short historical perspective. RSC Med. Chem.11(7), 760–770 (2020).
  • Singh A , GreningerP, RhodesDet al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell15(6), 489–500 (2009).
  • Prenen H , FakihM, FalchookGet al. SO-39 evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: exploratory plasma biomarker analysis of CodeBreaK 100. Ann. Oncol.33(Suppl. 4), S373 (2022).
  • Amodio V , YaegerR, ArcellaPet al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov.10(8), 1129–1139 (2020).
  • Ryan MB , CokerO, SorokinAet al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep.39(12), 110993 (2022).
  • Kuboki Y , YaegerR, FakihMet al. 45MO sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase Ib full expansion cohort. Ann. Oncol.33(Suppl. 9), S1445–S1446 (2022).
  • Yaeger R , WeissJ, Pelster MSet al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. New Engl. J. Med.388(1), 44–54 (2023).
  • Yaeger R , MezzadraR, SinopoliJet al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov.13(1), 41–55 (2023).
  • Canon J , RexK, SaikiAYet al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature575(7781), 217–223 (2019).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.